Biogen is an American biotech company based in Cambridge, Massachusetts. The company uses recombinant DNA technology, also known as biotechnology. This makes it possible to produce human proteins and therefore medicinal products with the help of microorganisms. The company continues to develop new substances and works on improving already approved molecules.
P/E ratio for Biogen (BIIB)
P/E ratio as of June 2025 (TTM): 12.5
According to Biogen's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 12.4897. At the end of 2024 the company had a P/E ratio of 13.6.
P/E ratio history for Biogen from 2001 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | 13.6 | -57.71% |
| 2023 | 32.2 | 144.26% |
| 2022 | 13.2 | -42.65% |
| 2021 | 23.0 | 130.16% |
| 2020 | 9.99 | 6.16% |
| 2019 | 9.41 | -32.3% |
| 2018 | 13.9 | -47.92% |
| 2017 | 26.7 | 59.61% |
| 2016 | 16.7 | -16.06% |
| 2015 | 19.9 | -27.01% |
| 2014 | 27.3 | -23.12% |
| 2013 | 35.5 | 40.52% |
| 2012 | 25.3 | 17.15% |
| 2011 | 21.6 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | 26.3 | 110.65% | 🇺🇸 USA |
 Gilead Sciences GILD | 22.8 | 82.71% | 🇺🇸 USA |
 AbbVie ABBV | 78.4 | 527.58% | 🇺🇸 USA |
 Pfizer PFE | 17.2 | 37.61% | 🇺🇸 USA |
 Johnson & Johnson JNJ | 16.5 | 32.05% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | -0.0676 | -100.54% | 🇺🇸 USA |
 Sanofi SNY | 16.7 | 33.66% | 🇫🇷 France |
 Bio-Rad Laboratories BIO | -3.04 | -124.34% | 🇺🇸 USA |
 Illumina ILMN | -14.9 | -219.50% | 🇺🇸 USA |
 Qiagen QGEN | 109 | 769.88% | 🇳🇱 Netherlands |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.